Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2025 BST			5-day change	1st Jan Change
547.96 ^USD	-3.97%		+1.83%	-23.07%

07-11	UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating	MT
07-10	Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating	MT

Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM

Published on 14/05/2024 at 14:00

Presenter Speech
Brian Abrahams (Analysts)

All right. Let's get started. Welcome, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets. Really pleased to have Regeneron

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating	07-11	MT
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating	07-10	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $688 From $662, Keeps Sector Perform Rating	07-07	MT
Healthcare Stocks Declined Ahead of Jobs Report -- Healthcare Roundup	07-02	DJ
US FDA approves Regeneron's blood cancer therapy	07-02	RE
US FDA approves Regeneron's blood cancer therapy	07-02	RE
Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac	07-02	CI
Regeneron Pharmaceuticals Gets Accelerated Approval From FDA for Multiple Myeloma Treatment	07-02	MT
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment	07-02	DJ
US FDA approves Regeneron's blood cancer therapy	07-02	RE
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index	06-30	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) added to Russell 1000 Dynamic Index	06-30	CI
Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy	06-30	MT
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Growth Index	06-30	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000E Growth Index	06-30	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell Top 200 Growth Index	06-30	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Growth-Defensive Index	06-30	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell Top 200 Growth Benchmark	06-29	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000E Growth Benchmark	06-29	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Benchmark	06-29	CI
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Growth Benchmark	06-29	CI
Nektar's lead drug candidate shows promise in eczema trial, shares soar	06-24	RE
European Medicines Regulator Recommends Approval of Alvotech's Eylea Biosimilar AVT06	06-23	MT
Global markets live: Accenture, Amazon, Google, Tesla, UniCredit…	06-20
Sector Update: Health Care Stocks Rise Premarket Friday	06-20	MT